Biomarker-enhanced Clinical Assessment Of Sepsis And AKI
SUMMARY
The rise and development of biomarkers in medicine have undergone dramatic changes in specificity, sensitivity, and, more importantly, goal-directed therapy. The ability to combine markers that help delineate sepsis, as well as early acute kidney injury (AKI), may prove to be a low-risk diagnostic test that will decrease multiple system organ failure (MSOF) in the current increased population with sepsis. The role of biomarkers — procalcitonin for sepsis, and the combination of TIMP2 and IGFBP7 for AKI — in this diagnostic and clinical scenario will be explored and discussed in terms of clinical relevance.
FEATURED EXPERT
Louis M. Guzzi, MD, FCCM
ACCESS THE WEBINAR
This session overviews clinical assessment of acute kidney injury using biomarkers.
Viewing time: 1 hour
PUBLISHED BY
Sepsis Alliance Institute
February 23, 2021
